Amgen
AMGNAMGN · Stock Price
Historical price data
Overview
Amgen is a foundational pillar of the global biotechnology industry, with a mission to serve patients by transforming the promise of science into therapies that restore health or save lives. The company has achieved a dominant market position through its deep expertise in biologics manufacturing, a diversified portfolio of blockbuster medicines, and a robust pipeline targeting major therapeutic areas including cardiovascular disease, obesity, oncology, and inflammation. Its strategy is centered on leveraging advanced technologies like AI and human genetics to accelerate innovation, expand its manufacturing footprint, and deliver long-term growth.
Technology Platform
A fully integrated biologics platform centered on using living cells to manufacture complex therapeutic proteins and antibodies, augmented by advanced human genetics, AI-driven discovery, and world-class manufacturing capabilities.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Actonel® + Denosumab | Osteoporosis | Phase 3 | |
| Denosumab | Lung Cancer Non-small Cell Stage IV | Phase 3 | |
| interferon γ-1b | Friedreich's Ataxia | Phase 3 | |
| Darbepoetin Alfa | Myelodysplastic Syndrome (MDS) | Phase 3 | |
| Denosumab | Osteogenesis Imperfecta | Phase 3 |
Funding History
1FDA Approved Drugs
25Opportunities
Risk Factors
Competitive Landscape
Amgen faces intense competition from large pharma (e.g., Novo Nordisk, Lilly in obesity; Merck, AstraZeneca in oncology) and agile biotechs. Its key competitive advantages are its world-class biologics manufacturing scale and reliability, its fully integrated R&D/commercial model, and its strong financial position enabling strategic business development.
Company Timeline
Founded in Thousand Oaks, United States
Debt: $5.0B
FDA Approval: PAVBLU
FDA Approval: BKEMV
FDA Approval: IMDELLTRA